Prostate Cancer
Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone - Abstract
September 16, 2011
Gleason score 7 prostate cancer on needle biopsy: Relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy - Abstract
September 15, 2011
Emerging therapies to prevent skeletal morbidity in men with prostate cancer - Abstract
September 15, 2011
Construct validity in a high-fidelity prostate exam simulator - Abstract
September 15, 2011
Role of pelvic lymph node dissection in prostate cancer treatment - Abstract
September 15, 2011
Prostate-specific antigen testing across the spectrum of prostate cancer - Abstract
September 15, 2011
Active-targeted nanotherapy strategies for prostate cancer - Abstract
September 15, 2011
T2*-weighted image/T2-weighted image fusion in postimplant dosimetry of prostate brachytherapy - Abstract
September 14, 2011
Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates - Abstract
September 14, 2011
Determination of action thresholds for electromagnetic tracking system-guided hypofractionated prostate radiotherapy using volumetric modulated arc therapy - Abstract
September 14, 2011
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer - Abstract
September 14, 2011
End points and outcomes in castration-resistant prostate cancer: From clinical trials to clinical practice - Abstract
September 14, 2011
Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically - Abstract
September 14, 2011
The combination of Serenoa repens, selenium and lycopene is more effective than Serenoa repens alone to prevent hormone dependent prostatic growth - Abstract
September 14, 2011
Association between saliva PSA and serum PSA in conditions with prostate adenocarcinoma - Abstract
September 13, 2011